Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Effective sirolimus treatment for refractory spindle cell haemangioma.

Ho CB, Hsieh K, Chen WY, Lin YT, Chiou JF, Lee HL, Shiah HS.

Br J Dermatol. 2018 Oct;179(4):976-977. doi: 10.1111/bjd.16739. Epub 2018 Jul 20. No abstract available.

PMID:
29750334
2.

CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.

Siddiqui-Jain A, Bliesath J, Macalino D, Omori M, Huser N, Streiner N, Ho CB, Anderes K, Proffitt C, O'Brien SE, Lim JK, Von Hoff DD, Ryckman DM, Rice WG, Drygin D.

Mol Cancer Ther. 2012 Apr;11(4):994-1005. doi: 10.1158/1535-7163.MCT-11-0613. Epub 2012 Jan 20.

3.

Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer.

Drygin D, Ho CB, Omori M, Bliesath J, Proffitt C, Rice R, Siddiqui-Jain A, O'Brien S, Padgett C, Lim JK, Anderes K, Rice WG, Ryckman D.

Biochem Biophys Res Commun. 2011 Nov 11;415(1):163-7. doi: 10.1016/j.bbrc.2011.10.046. Epub 2011 Oct 18.

PMID:
22027148
4.

Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.

Drygin D, Lin A, Bliesath J, Ho CB, O'Brien SE, Proffitt C, Omori M, Haddach M, Schwaebe MK, Siddiqui-Jain A, Streiner N, Quin JE, Sanij E, Bywater MJ, Hannan RD, Ryckman D, Anderes K, Rice WG.

Cancer Res. 2011 Feb 15;71(4):1418-30. doi: 10.1158/0008-5472.CAN-10-1728. Epub 2010 Dec 15.

5.

Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.

Drygin D, Siddiqui-Jain A, O'Brien S, Schwaebe M, Lin A, Bliesath J, Ho CB, Proffitt C, Trent K, Whitten JP, Lim JK, Von Hoff D, Anderes K, Rice WG.

Cancer Res. 2009 Oct 1;69(19):7653-61. doi: 10.1158/0008-5472.CAN-09-1304. Epub 2009 Sep 8.

6.

The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures.

Howes AL, Chiang GG, Lang ES, Ho CB, Powis G, Vuori K, Abraham RT.

Mol Cancer Ther. 2007 Sep;6(9):2505-14. Epub 2007 Aug 31.

7.

Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold.

Knight ZA, Chiang GG, Alaimo PJ, Kenski DM, Ho CB, Coan K, Abraham RT, Shokat KM.

Bioorg Med Chem. 2004 Sep 1;12(17):4749-59.

PMID:
15358300
8.

Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin.

Wipf P, Minion DJ, Halter RJ, Berggren MI, Ho CB, Chiang GG, Kirkpatrick L, Abraham R, Powis G.

Org Biomol Chem. 2004 Jul 7;2(13):1911-20. Epub 2004 Jun 14.

PMID:
15227545
9.

Scimitar syndrome.

Ho CB.

J Emerg Med. 2001 Oct;21(3):279-81. No abstract available.

PMID:
11604285

Supplemental Content

Support Center